Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
$1.40
-5.7%		$1.52
$1.31
▼
$8.34
$6.36M-2.0395,992 shs607,919 shs
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
$1.87
+0.5%		$2.71
$1.76
▼
$14.64
$6.35M1.8445,595 shs27,905 shs
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$0.40
+14.7%		$0.30
$0.23
▼
$2.75
$5.35M0.8442.10 million shs18.47 million shs
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
$0.23
+0.4%		$0.49
$0.22
▼
$3.09
$1.49M1.7615.00 million shs2.40 million shs
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
-5.74%-9.42%-20.29%-27.34%-70.44%
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
+0.54%-4.10%-20.43%-62.97%-83.99%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
+14.75%-23.13%+37.23%+42.77%-81.40%
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
+0.43%-17.31%-31.18%-58.29%-84.95%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
$1.40
-5.7%		$1.52
$1.31
▼
$8.34
$6.36M-2.0395,992 shs607,919 shs
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
$1.87
+0.5%		$2.71
$1.76
▼
$14.64
$6.35M1.8445,595 shs27,905 shs
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$0.40
+14.7%		$0.30
$0.23
▼
$2.75
$5.35M0.8442.10 million shs18.47 million shs
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
$0.23
+0.4%		$0.49
$0.22
▼
$3.09
$1.49M1.7615.00 million shs2.40 million shs
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
-5.74%-9.42%-20.29%-27.34%-70.44%
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
+0.54%-4.10%-20.43%-62.97%-83.99%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
+14.75%-23.13%+37.23%+42.77%-81.40%
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
+0.43%-17.31%-31.18%-58.29%-84.95%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
2.00
Hold$31.002,122.22% Upside
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
2.00
Hold$13.00595.19% Upside
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
1.00
SellN/AN/A
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest MTNB, CVKD, ENSC, and ACXP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
N/AN/AN/AN/A$2.07 per shareN/A
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
N/AN/AN/AN/A$1.17 per shareN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$5.07M1.21N/AN/A$0.63 per share0.63
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
$1.10M1.36N/AN/A$0.75 per share0.31
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
-$7.97M-$4.05N/AN/AN/AN/A-141.45%-96.50%N/A
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
-$13.24M-$5.63N/AN/AN/AN/A-476.34%-307.13%N/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$10.18M-$3.35N/AN/AN/A-280.53%-1,225.23%-295.90%N/A
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
-$10.35M-$3.89N/AN/AN/AN/A-140.25%-88.13%N/A

Latest MTNB, CVKD, ENSC, and ACXP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
-$0.3767-$0.53-$0.1533-$0.53N/AN/A
8/13/2026Q2 2026
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
-$1.42-$1.14+$0.28-$1.14N/AN/A
8/13/2026Q2 2026
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$0.50-$0.20+$0.30-$0.20$1.20 million$1.16 million
8/13/2026Q2 2026
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
N/A-$0.21N/A-$0.21N/AN/A
5/15/2026Q1 2026
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$0.73-$0.52+$0.21-$0.52$1.00 million$0.96 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
N/AN/AN/AN/AN/A
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
N/AN/AN/AN/AN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
N/AN/AN/AN/AN/A
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
N/A
3.78
3.78
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
N/A
2.68
2.68
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
N/A
0.71
0.71
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
N/A
1.32
1.32

Institutional Ownership

CompanyInstitutional Ownership
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
11.53%
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
7.92%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
5.63%
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
11.77%

Insider Ownership

CompanyInsider Ownership
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
20.30%
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
14.59%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
2.80%
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
4.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
34.30 million3.43 millionNo Data
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
43.42 million2.92 millionNot Optionable
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
1015.37 million14.94 millionNot Optionable
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
306.41 million6.11 millionN/A

Recent News About These Companies

GH Power, Matinas BioPharma join forces to create NYSE-listed clean energy company
July 13, 2026  |  msn.comhttps://www.msn.com/en-us/money/companies/gh-power-matinas-biopharma-join-forces-to-create-nyse-listed-clean-energy-company/ar-AA27Plxu
Matinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement ...
July 13, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/matinas-biopharma-announces-strategic-business-combination-with-gh-power-to-create-publicly-traded-advanced-clean-energy-and-green-hydrogen-company-signs-definitive-agreement-to-sell-lnc-platform-1036318373
Matinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity Pharmaceuticals
July 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/13/3326126/32419/en/matinas-biopharma-announces-strategic-business-combination-with-gh-power-to-create-publicly-traded-advanced-clean-energy-and-green-hydrogen-company-signs-definitive-agreement-to-se.html
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing ...
June 27, 2026  |  caledonianrecord.comC
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance
June 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/26/3318484/32419/en/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards-and-acceptance-of-plan-to-regain-compliance.html
Matinas BioPharma Holdings, Inc.
April 8, 2026  |  edition.cnn.comhttps://edition.cnn.com/markets/stocks/MTNB
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
April 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/matinas-biopharma-receives-notice-non-210000593.html
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
April 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/03/3268148/32419/en/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards.html
Matinas BioPharma Holdings, Inc. (MTNB) Restructures Amid Challenges, Focuses on Oral Antifungal MAT2203
September 24, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/matinas-biopharma-holdings-inc-mtnb-restructures-amid-challenges-focuses-on-oral-antifungal-mat2203/ar-AA1NaEt7
MTNB Matinas BioPharma Holdings, Inc. - Seeking Alpha
June 27, 2025  |  seekingalpha.comhttps://seekingalpha.com/symbol/MTNB
Matinas BioPharma Holdings, Inc. (MTNB) - Yahoo Finance
June 24, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/quote/MTNB/financials/
Kalkine Matinas BioPharma Surges Amid NYSE Composite Market Momentum
June 7, 2025  |  kalkinemedia.comK
Matinas BioPharma amends bylaws, updates on officer agreements
May 4, 2025  |  investing.comhttps://www.investing.com/news/sec-filings/matinas-biopharma-amends-bylaws-updates-on-officer-agreements-93CH-4020875
Matinas BioPharma files to sell 16.9M shares of common stock for holders
April 24, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/matinas-biopharma-files-to-sell-16-9m-shares-of-common-stock-for-holders-1034609950
Matinas BioPharma secures shareholder nods on key proposals
April 6, 2025  |  investing.comhttps://www.investing.com/news/sec-filings/matinas-biopharma-secures-shareholder-nods-on-key-proposals-93CH-3969300
Matinas BioPharma announces board chairman’s departure
March 16, 2025  |  investing.comhttps://www.investing.com/news/sec-filings/matinas-biopharma-announces-board-chairmans-departure-93CH-3930570
Matinas BioPharma appoints Murphy, Neugeboren to board of directors
March 11, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/matinas-biopharma-appoints-murphy-neugeboren-to-board-of-directors-1034463443
Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors
March 11, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/matinas-biopharma-appoints-seasoned-biotech-110000705.html
Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors
February 13, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/02/13/3026339/32419/en/matinas-biopharma-announces-agreement-for-the-acquisition-of-preferred-stock-and-appointment-of-dr-robin-l-smith-to-the-board-of-directors.html
Matinas BioPharma announces board member retirement
February 11, 2025  |  msn.comhttps://www.msn.com/en-us/money/companies/matinas-biopharma-announces-board-member-retirement/ar-AA1yQW5t

New MarketBeat Followers Over Time

Media Sentiment Over Time

Acurx Pharmaceuticals stock logo

Acurx Pharmaceuticals NASDAQ:ACXP

$1.40 -0.09 (-5.74%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$1.38 -0.02 (-1.29%)
As of 08/14/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Cadrenal Therapeutics stock logo

Cadrenal Therapeutics NASDAQ:CVKD

$1.87 +0.01 (+0.54%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$1.84 -0.03 (-1.34%)
As of 08/14/2026 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Ensysce Biosciences stock logo

Ensysce Biosciences NASDAQ:ENSC

$0.40 +0.05 (+14.75%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$0.36 -0.04 (-8.98%)
As of 08/14/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.

Matinas Biopharma stock logo

Matinas Biopharma NYSEAMERICAN:MTNB

$0.23 +0.00 (+0.43%)
As of 08/14/2026 04:10 PM Eastern

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas